ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01427946
Recruitment Status : Completed
First Posted : September 2, 2011
Last Update Posted : November 13, 2014
Sponsor:
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2014
  Actual Study Completion Date : October 2014